Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Multiple myeloma (MM) is a neoplastic plasma cell disorder characterized by the expansion and accumulation of clonal plasma cells. The introduction of novel drugs and new therapeutic options has led to significantly higher complete response rates and prolonged progression-free and overall survival (...

ver descrição completa

Detalhes bibliográficos
Autores: Maiolino, Angelo, Sobral da Costa, E., Orfao, Alberto
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2023
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/337522
Acesso em linha:http://hdl.handle.net/10261/337522
Access Level:Acceso aberto
Palavra-chave:Minimal residual disease
Multiple myeloma
Prognostic factor
Disease monitoring
Flow cytometry
id ES_85dfed0753a1a2f034fffb3443297d56
oai_identifier_str oai:digital.csic.es:10261/337522
network_acronym_str ES
network_name_str España
repository_id_str
spelling Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patientsMaiolino, AngeloSobral da Costa, E.Orfao, AlbertoMinimal residual diseaseMultiple myelomaPrognostic factorDisease monitoringFlow cytometryMultiple myeloma (MM) is a neoplastic plasma cell disorder characterized by the expansion and accumulation of clonal plasma cells. The introduction of novel drugs and new therapeutic options has led to significantly higher complete response rates and prolonged progression-free and overall survival (1). Despite these advances, MM remains an incurable disease. Thus, there is a need to refine response criteria and methods for more sensitive identification of persistence of lower levels of minimal (measurable) residual disease (MRD) (2). The International Myeloma Working Group has defined the response criteria for patients with MM by including MRD (3). Moreover, depth response based on MRD has emerged as one of the most important independent prognostic factors in MM and has been tested as a dynamic tool for treatment/disease monitoring, prognostication, and as a new (potential) therapeutic endpoint in clinical trials and drug approval for MM patients (4).Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2023202320232023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_b239Publisher's versioninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/contributionToPeriodicalhttp://hdl.handle.net/10261/337522reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.3389/fonc.2023.1211935Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3375222026-05-22T06:33:51Z
dc.title.none.fl_str_mv Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
title Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
spellingShingle Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
Maiolino, Angelo
Minimal residual disease
Multiple myeloma
Prognostic factor
Disease monitoring
Flow cytometry
title_short Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
title_full Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
title_fullStr Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
title_full_unstemmed Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
title_sort Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
dc.creator.none.fl_str_mv Maiolino, Angelo
Sobral da Costa, E.
Orfao, Alberto
author Maiolino, Angelo
author_facet Maiolino, Angelo
Sobral da Costa, E.
Orfao, Alberto
author_role author
author2 Sobral da Costa, E.
Orfao, Alberto
author2_role author
author
dc.contributor.none.fl_str_mv Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Minimal residual disease
Multiple myeloma
Prognostic factor
Disease monitoring
Flow cytometry
topic Minimal residual disease
Multiple myeloma
Prognostic factor
Disease monitoring
Flow cytometry
description Multiple myeloma (MM) is a neoplastic plasma cell disorder characterized by the expansion and accumulation of clonal plasma cells. The introduction of novel drugs and new therapeutic options has led to significantly higher complete response rates and prolonged progression-free and overall survival (1). Despite these advances, MM remains an incurable disease. Thus, there is a need to refine response criteria and methods for more sensitive identification of persistence of lower levels of minimal (measurable) residual disease (MRD) (2). The International Myeloma Working Group has defined the response criteria for patients with MM by including MRD (3). Moreover, depth response based on MRD has emerged as one of the most important independent prognostic factors in MM and has been tested as a dynamic tool for treatment/disease monitoring, prognostication, and as a new (potential) therapeutic endpoint in clinical trials and drug approval for MM patients (4).
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_b239
Publisher's version
info:eu-repo/semantics/publishedVersion
dc.type.openaire.fl_str_mv info:eu-repo/semantics/contributionToPeriodical
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/337522
url http://hdl.handle.net/10261/337522
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.3389/fonc.2023.1211935
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412332571983872
score 15,198674

Registros relacionados